Learn more

NGUYEN MARK QUANG

Overview
  • Total Patents
    35
  • GoodIP Patent Rank
    47,224
  • Filing trend
    ⇩ 100.0%
About

NGUYEN MARK QUANG has a total of 35 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2013. It filed its patents most often in United States and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets organic fine chemistry, pharmaceuticals and environmental technology are LUDWIG HEUMANN & CO CHEM PHARM, NANJING HAIAOSI BIOMEDICINE TECH CO LTD and RECH S ET PROPAGANDE SCIENT.

Patent filings in countries

World map showing NGUYEN MARK QUANGs patent filings in countries
# Country Total Patents
#1 United States 29
#2 WIPO (World Intellectual Property Organization) 6

Patent filings per year

Chart showing NGUYEN MARK QUANGs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Nguyen Mark Quang 33
#2 Gangakhedkar Archana 2
#3 Nguyen Mark 2

Latest patents

Publication Filing date Title
US9963428B1 Bucillamine prodrugs, pharmaceutical compositions thereof, and methods of use
WO2018174839A1 Cysteine, n-acetylcysteine and penicillamine prodrugs, pharmaceutical compositions thereof, and methods of use
WO2018174838A1 Cysteamine prodrugs, related analogs, pharmaceutical compositions thereof, and methods of use
US2016297770A1 Fumarate compounds, pharmaceutical compositions thereof, and methods of use
US2017129867A1 Tiopronin prodrugs, pharmaceutical compositions thereof, and methods of use
US2017129868A1 Trientine prodrugs, pharmaceutical compositions thereof, and methods of use
US2017081280A1 Cysteine, N-acetylcysteine, and penicillamine related compounds, pharmaceutical compositions thereof, and methods of use
US2017081279A1 Cysteamine prodrugs, pharmaceutical compositions thereof, and methods of use
US9532968B1 Fumarate compounds, pharmaceutical compositions thereof, and methods of use
US2017056358A1 Fumarate compounds, pharmaceutical compositions thereof, and methods of use
US9403784B1 Fumarate compounds, pharmaceutical compositions thereof, and methods of use
US2017022149A1 Fumarate compounds, pharmaceutical compositions thereof, and methods of use
US2017022147A1 Fumarate compounds, pharmaceutical compositions thereof, and methods of use
US2017020837A1 Fumarate compounds, pharmaceutical compositions thereof, and methods of use
US2017022153A1 Fumarate compounds, pharmaceutical compositions thereof, and methods of use
US2017008835A1 Fumarate compounds, pharmaceutical compositions thereof, and methods of use
US2017008834A1 Fumarate compounds, pharmaceutical compositions thereof, and methods of use
US2017001952A1 Fumarate compounds, pharmaceutical compositions thereof, and methods of use
US2017001953A1 Fumarate compounds, pharmaceutical compositions thereof, and methods of use
US9394312B1 Ibrutinib prodrugs, pharmaceutical compositions thereof, and methods of use